Log in

Relevant bibliographies by topics / Graft rejection; Tumours; Autoimmune diseases

Contents

Journal articles
Dissertations / Theses
Book chapters

Academic literature on the topic 'Graft rejection; Tumours; Autoimmune diseases'

Author: Grafiati

Published: 4 June 2021

Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Graft rejection; Tumours; Autoimmune diseases.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Graft rejection; Tumours; Autoimmune diseases"

1

Lee, Gap Ryol. "Phenotypic and Functional Properties of Tumor-Infiltrating Regulatory T Cells." Mediators of Inflammation 2017 (2017): 1–9. http://dx.doi.org/10.1155/2017/5458178.

Full text

Abstract:

Regulatory T (Treg) cells maintain immune homeostasis by suppressing excessive immune responses. Treg cells induce tolerance against self- and foreign antigens, thus preventing autoimmunity, allergy, graft rejection, and fetus rejection during pregnancy. However, Treg cells also infiltrate into tumors and inhibit antitumor immune responses, thus inhibiting anticancer therapy. Depleting whole Treg cell populations in the body to enhance anticancer treatments will produce deleterious autoimmune diseases. Therefore, understanding the precise nature of tumor-infiltrating Treg cells is essential fo

APA, Harvard, Vancouver, ISO, and other styles

2

Storb, Rainer F., Guido Lucarelli, Peter A. McSweeney, and Richard W. Childs. "Hematopoietic Cell Transplantation for Benign Hematological Disorders and Solid Tumors." Hematology 2003, no. 1 (2003): 372–97. http://dx.doi.org/10.1182/asheducation.v2003.1.372.0010372.

Full text

Abstract:

Allogeneic hematopoietic cell transplantation (HCT) has been successfully used as replacement therapy for patients with aplastic anemia and hemoglobinopathies. Both autologous and allogeneic HCT following high-dose chemotherapy can correct manifestations of autoimmune diseases. The impressive allogeneic graft-versus-tumor effects seen in patients given HCT for hematological malignancies have stimulated trials of allogeneic immunotherapy in patients with otherwise refractory metastatic solid tumors. This session will update the status of HCT in the treatment of benign hematological diseases and

APA, Harvard, Vancouver, ISO, and other styles

3

Storb, Rainer F., Guido Lucarelli, Peter A. McSweeney, and Richard W. Childs. "Hematopoietic Cell Transplantation for Benign Hematological Disorders and Solid Tumors." Hematology 2003, no. 1 (2003): 372–97. http://dx.doi.org/10.1182/asheducation-2003.1.372.

Full text

Abstract:

Abstract Allogeneic hematopoietic cell transplantation (HCT) has been successfully used as replacement therapy for patients with aplastic anemia and hemoglobinopathies. Both autologous and allogeneic HCT following high-dose chemotherapy can correct manifestations of autoimmune diseases. The impressive allogeneic graft-versus-tumor effects seen in patients given HCT for hematological malignancies have stimulated trials of allogeneic immunotherapy in patients with otherwise refractory metastatic solid tumors. This session will update the status of HCT in the treatment of benign hematological dis

APA, Harvard, Vancouver, ISO, and other styles

4

Im, Ho Joon, Kyung Nam Koh, Jin Kyung Suh, et al. "Haploidentical Hematopoietic Stem Cell Transplantation in Pediatric Patients: Comparison of Early Post-Transplant Outcome According to in Vitro Depletion Method." Blood 124, no. 21 (2014): 1229. http://dx.doi.org/10.1182/blood.v124.21.1229.1229.

Full text

Abstract:

Abstract Currently, haploidentical hematopoietic cell transplantation (HHCT) is considered an established option for patients who have diseases curable with HCT but who lack a suitable donor. We compared the early post-transplant outcomes of the two transplant groups using different in vitro depletion method. Between July 2008 and June 2014, 49 pediatric patients underwent in vitro T cell-depleted HHCT. Of 49 patients, 28 received CD3-depleted stem cells (CD3-HHCT) and 21 received TCRαβ-depleted grafts (TCRαβ-HHCT). Among 28 patients of CD3-HHCT, nine had hematologic malignancy [HM, one with A

APA, Harvard, Vancouver, ISO, and other styles

5

Emerson, Amy E., Emily M. Slaby, Shivani C. Hiremath, and Jessica D. Weaver. "Biomaterial-based approaches to engineering immune tolerance." Biomaterials Science 8, no. 24 (2020): 7014–32. http://dx.doi.org/10.1039/d0bm01171a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Bordron, A., A. Mankaï, B. Bendaoud, et al. "B Cell-Ablative Therapy: Where are We Now?" International Journal of Immunopathology and Pharmacology 20, no. 4 (2007): 655–59. http://dx.doi.org/10.1177/039463200702000401.

Full text

Abstract:

Based on their multifaceted functions, B cells participate in several pathological settings such as lymphoproliferative disorders, autoimmune diseases and graft rejection. B cell-ablative therapy has thus emerged as a mainstay in these diseases. A number of anti-B cell antibodies (Abs) have been generated, among which anti-CD20 Abs appear to be efficient. Rituximab (RTX) is one of these anti-CD20 monoclonal Abs. Originally approved for the treatment of non-Hodgkin lymphoma, RTX is now being administered in other malignant proliferations, applied to an increasing number of autoimmune diseases a

APA, Harvard, Vancouver, ISO, and other styles

7

Niemand, Claudia, Carina Conrads, Ramona Siemer, and Mario Assenmacher. "Rapid Clinical Scale Isolation of CD25hiCD4+ Regulatory T Cells." Blood 104, no. 11 (2004): 4969. http://dx.doi.org/10.1182/blood.v104.11.4969.4969.

Full text

Abstract:

Abstract Several publications during the last few years have reported CD25hiCD4+ regulatory T cells (Tregs) to prevent or to reverse disease in different mouse models of experimental autoimmune encephalomyelitis (EAE), colitis, graft rejection and graft-versus-host-disease (GvHD). As mouse and human Tregs share many phenotypical and functional characteristics, Tregs could provide a promising therapeutic approach for various human autoimmune diseases and pathological alloresponses. Here we have shown that Tregs can be isolated from leukapheresis harvests by CD25 enrichment using the CliniMACS t

APA, Harvard, Vancouver, ISO, and other styles

8

Jenh, Chung-Her, Mary Ann Cox, Long Cui, et al. "A selective and potent CXCR3 antagonist SCH 546738 attenuates the development of autoimmune diseases and delays graft rejection." BMC Immunology 13, no. 1 (2012): 2. http://dx.doi.org/10.1186/1471-2172-13-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Kaouther, Mnasria, and Oueslati Ridha. "Dendritic Cell-Based Graft Tolerance." ISRN Pharmacology 2011 (April 10, 2011): 1–4. http://dx.doi.org/10.5402/2011/347134.

Full text

Abstract:

It has recently been demonstrated that mouse and human dendritic cells (DCs) can produce IL-2 after activation. However the role of the IL2/IL2R pathway in DC functions has not yet been fully elucidated. The results presented in this study provide several new insights into the role of this pathway in DCs. We report that stimulation of human monocyte-derived DCs with LPS strongly upregulated CD25 (α chain of the IL2R) expression. In additon, by using a humanized monoclonal antibody against CD25, we demonstrated that the IL2 signalling in DC upregulated both IL-12 and γIFN production but decreas

APA, Harvard, Vancouver, ISO, and other styles

10

Zulpaite, Ruta, Povilas Miknevicius, Bettina Leber, Kestutis Strupas, Philipp Stiegler, and Peter Schemmer. "Tryptophan Metabolism via Kynurenine Pathway: Role in Solid Organ Transplantation." International Journal of Molecular Sciences 22, no. 4 (2021): 1921. http://dx.doi.org/10.3390/ijms22041921.

Full text

Abstract:

Solid organ transplantation is a gold standard treatment for patients suffering from an end-stage organ disease. Patient and graft survival have vastly improved during the last couple of decades; however, the field of transplantation still encounters several unique challenges, such as a shortage of transplantable organs and increasing pool of extended criteria donor (ECD) organs, which are extremely prone to ischemia-reperfusion injury (IRI), risk of graft rejection and challenges in immune regulation. Moreover, accurate and specific biomarkers, which can timely predict allograft dysfunction a

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Graft rejection; Tumours; Autoimmune diseases"

1

Chinaelli, Marco. "99mTc labelling of interleukin-2 for in-vivo detection of lymphocytic infiltration." Thesis, Queen Mary, University of London, 1996. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.243365.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Lambert, Julie. "Autoimmune Diabetes and Transplantation Tolerance Induced by Costimulation Blockade in NOD Mice: a Dissertation." eScholarship@UMMS, 2007. https://escholarship.umassmed.edu/gsbs_diss/344.

Full text

Abstract:

NOD mice model human type 1 diabetes and have been used to investigate tolerance induction protocols for islet transplantation in a setting of autoimmunity. Costimulation blockade-based tolerance protocols that induce prolonged skin and permanent islet allograft survival in non-autoimmune mice have failed in NOD mice. To investigate the underlying mechanisms, we generated NOD hematopoietic chimeras. We were able to show that dendritic cell maturation defects seen in NOD mice are partially corrected in mixed hematopoietic chimeras. Furthermore, skin allograft survival was dependent upon the phe

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Graft rejection; Tumours; Autoimmune diseases"

1

Nocentini, Giuseppe, Luigi Cari, Graziella Migliorati, and Carlo Riccardi. "Treatment of Autoimmune Diseases and Prevention of Transplant Rejection and Graft-Versus-Host Disease by Regulatory T Cells: The State of the Art and Perspectives." In The Epigenetics of Autoimmunity. Elsevier, 2018. http://dx.doi.org/10.1016/b978-0-12-809912-4.00016-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!